ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA)

zzlangerhans (99.67) Submitted: 2/14/2012 7:30:33 PM : Start Price: $8.38 ISTA Score: -10.31

ISTA has surprisingly maintained the dramatic elevation in share price that came about due to Valeant's takeout bid, despite the fact that Valeant has moved on from the stalled negotiations and purchased Eyetech instead. The share price is nearly triple the low of 3.11 seen in October after disappointing revenue growth, failure of phase III trials of Remura in dry eye, and broad market weakness.

The street may still be buying ISTA's high self-esteem but I'm seeing little in the way of pipeline catalysts to provide scaffolding for the lofty share price. If the company isn't able to provide growth in revenues and steady profits in the first two quarters of 2012 there's little to prevent a return to the 4 range.

Metalcurious (47.51) Submitted: 2/14/2012 12:20:24 AM : Start Price: $8.16 ISTA Score: +13.42

ISTA will likely be coming out with a new dry eye treatment, REMURA, that I would expect to become a leader in the huge but underserved dry eye market. I believe foul play was involved in suppressing their Corneaplasty procedure from coming to the market.

natylupe (< 20) Submitted: 12/18/2011 11:04:07 AM : Start Price: $6.68 ISTA Score: +27.70

Many baby boomers retiring. Many people suffer from debilitating eye diseases.

EclecticRecluse (77.78) Submitted: 5/16/2011 7:36:54 AM : Start Price: $10.05 ISTA Score: -8.56

Relative Pullback Likely Complete, Rise to Resume

Swervinm (40.56) Submitted: 1/12/2011 4:05:35 PM : Start Price: $6.05 ISTA Score: +47.38

With the amount of pain medicine I take because of my Military Disability this company should always outperform the S&P 500.

lonewulf47638 (51.51) Submitted: 4/12/2010 3:07:23 PM : Start Price: $3.81 ISTA Score: +128.14

Xibrom continues to lead the market. A catalyst will be the Xibrom-once daily mid 2010 approval date. I'm looking for big pharma to watch Ista grow. Give it a year to rose.

psaigal21 (79.16) Submitted: 12/16/2009 11:24:38 PM : Start Price: $4.32 ISTA Score: +90.88

ISTA just hired a significant number of sales reps and is really ramping up its efforts to recruit and invest in good sales talent. This stock will be a 4-5 bagger relatively quickly as the economy turns around and the drugs it sells become more well known. I will be purchasing some shares each time the stock dips w/ the overall market in hopes of dollar cost averaging over the next year or so.

twsun21 (< 20) Submitted: 9/17/2009 12:49:08 AM : Start Price: $5.13 ISTA Score: +53.15

way undervalued.

michaeltbryant (< 20) Submitted: 9/13/2009 10:12:27 PM : Start Price: $5.23 ISTA Score: +45.84

Come on. P/E of 0.00. Just got FDA approval.

stuartcreekfarms (55.94) Submitted: 2/24/2008 12:35:34 PM : Start Price: $4.17 ISTA Score: +116.17

Promising drugs for eye disease.
Stock near a 52-week low

eyedocarun (86.80) Submitted: 7/11/2007 9:21:07 PM : Start Price: $7.27 ISTA Score: +33.64

I'm an eye doc so I have a little insight into the core products offered by ISTA. Their beta-blocker Istalol is just an okay product, but I'm very optimistic about the future of their other product Xibrom, which is a non-steroidal anti-inflammatory drop with many clinical uses...it sets itself apart from others in its class by being twice/day versus 4x/day dosage...soon it will be once/day and then the product is in a class by itself. I'm optimistic about their pipeline, especially their upcoming Steroid-Antibiotic combo and dry eye drops. There's a lot of potential for this company and they're on the right track. They need to get bigger with their sales force to really push their products and the recent stock sale will help with that.

notmyleg (55.94) Submitted: 5/10/2007 11:36:10 AM : Start Price: $6.31 ISTA Score: +51.03

The fact that this stock lost 30 percent of its value is just stupid. They have many products in trial besides T-Pred, and are likely to eventually receive approval for that anyway.

This is absolutely NOT a safety issue as some have claimed, that would be potentially bad. Rather, there is a dispute as to whether the drug is effective enough. They may have to conduct further trials, but they will probably get T-Pred approved.

Aaaashby (91.71) Submitted: 4/27/2007 10:55:50 PM : Start Price: $10.25 ISTA Score: -4.74

I bought around 8. I'll still recommend it around 10 even though you might be better off waiting for it to dip a bit. However, if you look at the miniscule market cap on this stock, there's plenty of room for it to be a ten or twenty bagger over the next five years.

I'm buy and hold on ISTA.